HAL Allergy introduces Scientific Advisory Board


LEIDEN - the Netherlands – HAL Allergy B.V. today introduces their Scientific Advisory Board. This group of specialists will advise and assist the company in order to realize its future plans. The successful kick-off meeting took place on October 6th in Leiden.

The introduction of the Scientific Advisory Board is an important step in the further development of the organization. In 2011 HAL Allergy started an ambitious clinical development program. The new scientific board will support the company in its ambitious projects and will contribute to the future R & D program.

The expertise of the Scientific Advisory Board is vast:

Prof. Dr. Ronald van Ree – Professor of Molecular and Translational Allergology at Academic Medical Centre / University of Amsterdam. Also member of the Executive Committee EAACI and Chairman of the Scientific Advisory Board
Prof. Dr. Fatima Ferreira – Vice President for research at Salzburg University. Also Head of Christian Doppler Laboratory for Allergy Diagnosis and Therapy
Dr. Moisés Calderón – Director Clinical Trials Unit at Imperial College, section of Allergy and Clinical Immunology. Also Chairman EAACI interest group Immunotherapy
Dr. Oliver Pfaar – ENT Specialist at Centre for Rhinology and Allergology at the University Hospital Mannheim. Also Secretary EAACI interest group Immunotherapy

“We are proud at HAL Allergy to welcome this team of prominent scientists within the field of allergy and immunotherapy” says Harry Flore, CEO of the HAL Allergy Group. “Their contribution and expertise will be of great value to our company. Their willingness to be part of our Scientific Advisory Board underlines that we are on the right track to realize our future goals and our innovative R & D program.”

About HAL Allergy
The HAL Allergy Group was established in 1959 and is an important European manufacturer of allergy vaccines and diagnostics. The Group's products are distributed through subsidiaries in Germany, Spain, Italy, Poland, Austria and the Benelux as well as a network of distribution partners around Europe. Currently HAL Allergy employs over 270 people throughout Europe with more than 160 situated in the Netherlands HQ. The German subsidiary in Düsseldorf, in operation since 1977 and one of the top three players in the largest allergy market, employs 60 people and is the main sales and marketing operation for the HAL Allergy Group. The main shareholder of HAL Allergy GmbH is Droege International Group AG, headquartered in Düsseldorf, Germany. More information is available on:

PDF version of this press release